Global Multi-Cancer Early Detection Market, By Type (Liquid Biopsy, Gene Panel, LDT, Others), By End-Use (Hospitals, Diagnostic Laboratories, Others) – Industry Trends and Forecast to 2031.
Multi-Cancer Early Detection Market Analysis and Size
The incidence of several types of cancers has been increasing globally and due to rising advancements in diagnostic procedures, the market is expected to witness a lucrative growth in the forecast period. The integration of data analytics and artificial intelligence technologies in the cancer detection may fuel the market growth.
Data Bridge Market Research analyses that the global multi-cancer early detection market which was USD 2.31 billion in 2023, would reach up to USD 7.07 billion by 2031, and is expected to undergo a CAGR of 15.02% during the forecast period. The “hospitals” in end users segment is expected to dominate the global multi-cancer early detection market due to presence of skilled professionals and advanced equipment in the hospital setting. In addition to the insights on market scenarios such as market value, growth rate, segmentation, geographical coverage, and major players, the market reports curated by the Data Bridge Market Research also include depth expert analysis, patient epidemiology, pipeline analysis, pricing analysis, and regulatory framework.
Report Scope and Market Segmentation
|
Report Metric
|
Details
|
|
Forecast Period
|
2024 to 2031
|
|
Base Year
|
2023
|
|
Historic Years
|
2022 (Customizable to 2016-2021)
|
|
Quantitative Units
|
Revenue in USD Billion, Volumes in Units, Pricing in USD
|
|
Segments Covered
|
Type (Liquid Biopsy, Gene Panel, LDT, Others), By End-Use (Hospitals, Diagnostic Laboratories, Others)
|
|
Countries Covered
|
U.S., Canada, Mexico, Germany, France, U.K., Belgium, Lithuania, Austria, Ireland, Norway, Poland, Italy, Spain, Russia, Turkey, Netherlands Switzerland, Rest of Europe, Japan, China, South Korea, India, Australia, Singapore, Thailand, Malaysia, Indonesia, Philippines, Rest of Asia-Pacific, Brazil, Argentina, Rest of South America, South Africa, Saudi Arabia, U.A.E., Egypt, Israel and Rest of Middle East and Africa
|
|
Market Players Covered
|
Micronoma, INC., (U.S.), ANPAC Bio-Medical Science Co., Ltd (U.S.), EARLYDIAGNOSTICS (U.S.), Early is Good (U.S.), CanSense Ltd (U.S.), Freenome Holdings, Inc. (U.S.), Oncocyte Corporation (U.S.), SeekIn, Inc. (U.S.), Naveris (U.S.), VESEN, Inc. (U.S.), Grail, LLC (Illumina, Inc.) (U.S.), Exact Sciences Corporation (U.S.), FOUNDATION MEDICINE, INC. (U.S.), Guangzhou AnchorDx Medical Co., Ltd. (China), Guardant Health (U.S.), Burning Rock Biotech Limited (China), Genecast Biotechnology Co., Ltd (China), Singlera Genomics, Inc. (U.S.)
|
|
Market Opportunities
|
|
Market Definition
Multi-cancer early detection refers to the identification of various types of cancer in the body at an early stage using advanced screening techniques. Unlike traditional cancer screenings that focus on specific types of cancer, multi-cancer early detection methods aim to detect a wide range of cancers simultaneously. These approaches often involve analyzing biological samples such as blood, urine, or tissue using molecular and genetic technologies to detect specific biomarkers or abnormalities associated with cancerous growth across different organs or tissues. The primary goal of multi-cancer early detection is to improve survival rates by detecting cancers before they spread or become symptomatic, thus enabling timely intervention and treatment.
Global Multi-Cancer Early Detection Market Dynamics
Drivers
- Increasing Cancer Incidence
The global incidence of cancer has been steadily rising due to factors such as aging populations, lifestyle changes, environmental factors, and improved diagnostic capabilities. With cancer becoming a leading cause of morbidity and mortality worldwide, there is a pressing need for more effective screening methods to detect the disease at its earliest stages. Multi-cancer early detection addresses this need by offering a comprehensive approach that can potentially identify various cancer types simultaneously, allowing for timely intervention and treatment initiation.
- Advancements in Data Analytics and Artificial Intelligence (AI)
The integration of data analytics and AI technologies has revolutionized cancer detection and diagnosis. These advancements enable the processing and analysis of vast amounts of clinical and molecular data, including genomics, proteomics, and imaging results, to identify subtle patterns and abnormalities indicative of cancer. Machine learning algorithms, in particular, have shown promise in improving the accuracy and efficiency of multi-cancer screening tests by continuously learning from new data and refining their predictive models. By leveraging AI-driven analytics, healthcare providers can make more informed decisions regarding patient risk assessment, screening protocols, and treatment strategies, ultimately enhancing the effectiveness of multi-cancer early detection programs and advancing the fight against cancer.
Opportunities
- Expanded Screening Programs
The growth of the global multi-cancer early detection market creates opportunities for governments, healthcare organizations, and insurance providers to implement comprehensive screening programs. These programs can target populations at high risk for cancer and offer accessible, cost-effective screening options to the general public. By investing in proactive screening initiatives, stakeholders can detect cancers earlier, reduce treatment costs, and improve long-term patient outcomes while addressing the increasing burden of cancer on healthcare systems.
- Precision Medicine and Targeted Therapies
Multi-cancer early detection aligns with the principles of precision medicine by enabling the identification of specific biomarkers and genetic mutations associated with different cancer types. This knowledge facilitates the development of targeted therapies and personalized treatment regimens tailored to individual patients' molecular profiles. By integrating multi-cancer screening with precision oncology approaches, clinicians can optimize treatment selection, minimize adverse effects, and improve overall survival rates for patients with various types of cancer.
Restraints/Challenges
- Validation and Regulatory Hurdles
The process of developing and validating multi-cancer screening tests involves extensive clinical trials and regulatory submissions to demonstrate safety, efficacy, and clinical utility. Navigating the complex regulatory landscape, which varies across different regions and jurisdictions, adds significant time and costs to the development timeline. In addition, ensuring compliance with evolving regulatory requirements and guidelines presents ongoing challenges for companies seeking to bring multi-cancer screening tests to market.
- Cost and Affordability
The high cost of multi-cancer screening tests, coupled with the expenses associated with follow-up diagnostic procedures, presents a significant barrier to widespread adoption and accessibility. Without adequate reimbursement mechanisms and insurance coverage, patients may face financial burdens and disparities in access to early detection services. Addressing cost concerns through innovative pricing models, reimbursement strategies, and cost-effectiveness analyses is crucial to improving affordability and equitable access to multi-cancer screening technologies.
This global multi-cancer early detection market report provides details of new recent developments, trade regulations, import-export analysis, production analysis, value chain optimization, market share, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on the global multi-cancer early detection market contact Data Bridge Market Research for an analyst brief, our team will help you take an informed market decision to achieve market growth.
Global Multi-Cancer Early Detection Market Scope
The global multi-cancer early detection market is segmented on the basis of type and end user. The growth amongst these segments will help you analyze meagre growth segments in the industries and provide the users with a valuable market overview and market insights to help them make strategic decisions for identifying core market applications.
Type
- Liquid Biopsy
- Gene Panel
- LDT
- Others
End User
- Hospitals
- Diagnostic Laboratories
- Others
Global Multi-Cancer Early Detection Market Regional Analysis/Insights
The global multi-cancer early detection market is analyzed and market size insights and trends are provided by country, type, and end users as referenced above.
U.S., Canada, Mexico, Germany, France, U.K., Belgium, Lithuania, Austria, Ireland, Norway, Poland, Italy, Spain, Russia, Turkey, Netherlands Switzerland, Rest of Europe, Japan, China, South Korea, India, Australia, Singapore, Thailand, Malaysia, Indonesia, Philippines, Rest of Asia-Pacific, Brazil, Argentina, Rest of South America, South Africa, Saudi Arabia, U.A.E., Egypt, Israel and Rest of Middle East and Africa.
North America region dominates the global multi-cancer early detection market due to the rising innovation in medical technology and rising investments by major market players in the for early detection of multiple types of cancer.
Asia-Pacific region is expected to grow at the highest growth rate in the global multi-cancer early detection market in forecast period due to the rising health awareness among the people and growing demand of advanced medical technology. Rising ageing population and rising number of cancer patients is further expected to fuel the growth of Asia-Pacific region in the forecast period.
The country section of the report also provides individual market impacting factors and changes in regulation in the market domestically that impacts the current and future trends of the market. Data points such as down-stream and upstream value chain analysis, technical trends and porter's five forces analysis, case studies are some of the pointers used to forecast the market scenario for individual countries. Also, the presence and availability of global brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of domestic tariffs and trade routes are considered while providing forecast analysis of the country data.
Healthcare Infrastructure Growth Installed Base and New Technology Penetration
The global multi-cancer early detection market also provides you with detailed market analysis for every country growth in healthcare expenditure for capital equipment, installed base of different kind of products for global multi-cancer early detection market, impact of technology using life line curves and changes in healthcare regulatory scenarios and their impact on the global multi-cancer early detection market. The data is available for historic period 2016-2021.
Competitive Landscape and Global Multi-Cancer Early Detection Market Share Analysis
The global multi-cancer early detection market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, global presence, production sites and facilities, production capacities, company strengths and weaknesses, product launch, product width and breadth, application dominance. The above data points provided are only related to the companies' focus related to the global multi-cancer early detection market.
Some of the major players operating in the global multi-cancer early detection market are:
- Micronoma, INC., (U.S.)
- ANPAC Bio-Medical Science Co., Ltd (U.S.)
- EARLYDIAGNOSTICS (U.S.)
- Early is Good (U.S.)
- CanSense Ltd (U.S.)
- Freenome Holdings, Inc. (U.S.)
- Oncocyte Corporation (U.S.)
- SeekIn, Inc. (U.S.)
- Naveris (U.S.)
- VESEN, Inc. (U.S.)
- Grail, LLC (Illumina, Inc.) (U.S.)
- Exact Sciences Corporation (U.S.)
- FOUNDATION MEDICINE, INC. (U.S.)
- Guangzhou AnchorDx Medical Co., Ltd. (China)
- Guardant Health (U.S.)
- Burning Rock Biotech Limited (China)
- Genecast Biotechnology Co., Ltd (China)
- Singlera Genomics, Inc. (U.S.)
SKU-